ASX:ACW

Livewire Exclusive

Positive results announced by Biogen, Anavex, and Lilly, along with Avanir's acquisition by Otsuka Pharma for US$3.5 billion have sparked renewed investor interest in Alzheimer’s drugs. Earlier this year, Axovant, a clinical-stage biotech focused on dementia treatments, pulled off one of the biggest biotech IPO in history with shares almost... Show More